Favourable results were seen in one patient with ALK-rearranged signet-ring cell carcinoma of the lung, who presented complete response after WBRT and crizotinib beyond progression (BP) (case 1) [14] and in another patient who had SD after SRS as monotherapy (case 6) [16]. The gene discussed is ALK; the disease is lung signet ring cell carcinoma.